Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26051626 | 0.78 | ALDH1A1 (0.34) | BAZ2BHDAC6CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL31595730 | 0.76 | KMT2A (0.39) | CYP1A2CYP3A4 | |
| SCHEMBL26206453 | 0.73 | ALDH1A1 (0.43) | HDAC6CYP1A2CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL31597152 | 0.73 | CYP2C9 (0.37) | CYP1A2CYP3A4 | |
| SCHEMBL31595885 | 0.72 | COMT (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31595830 | 0.72 | CYP11B2 (0.39) | HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL31595701 | 0.69 | HIF1A (0.35) | — | |
| SCHEMBL31597272 | 0.68 | COMT (0.39) | CYP1A2CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL21233179 | 0.67 | TSHR (0.44) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31595781 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | BAZ2B 3900/4885HDAC6 3096/4885CYP1A2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.